Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors.

Date publication

avril 2023

Journal

Expert opinion on pharmacotherapy

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Goetsch A, D'Amico F, Allocca M, Fiorino G, Furfaro F, Zilli A, Parigi TL, Radice S, Peyrin-Biroulet L, Danese S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37038911

Résumé

Janus kinase (JAK) inhibitors are an emerging class of small-molecule drugs, providing targeted therapy for a variety of diseases, and have made their way into the treatment of armamentarium of ulcerative colitis (UC) in recent years.

Mots clés

Filgotinib, JAK1, Upadacitinib, ivarmacitinib, ulcerative colitis

Référence

Expert Opin Pharmacother. 2023 04 11;:1-13